Novartis Ag

Dana-farber-cancer Institute Inc.

Oregon Health & Science University

Elisabeth Buchdunger

Doriano Fabbro

Carl-Henrik Heldin

Peter Traxler

Terence O'Reilly

Brian Jay Druker

Markus Wartmann

Jonathan A Fletcher

John David Rothermel

Michael C Heinrich

George Daniel Demetri

Ralf Brandt

Sandra Leta Silberman

Heikki Joensuu

Kristian Pietras

Arne Östman

Renaud Capdeville

Sasa Dimitrijevic

David Tuveson

The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT is administered.

Inhibitors of the mutant form of kit

The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT selected form midostaurin, vatalanib and compound A is administered. 

The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.

Combination comprising a signal transduction inhibitor and an epothilone derivative

4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula Ior a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.

Treatment of gastrointestinal stromal tumors

Growing community of inventors

Neuenburg, Germany

Elisabeth Buchdunger